Key facts
- This page summarizes Lynx1 Capital Management LP's Form 4 filing for Korro Bio, Inc. (KRRO).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Aug 2026, 09:54.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
Purchase
Purchase
Additional SEC filing notes
Footnote F1
The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.39 to $11.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.